Cargando…
Organ-Specific Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Monotherapy Versus Combination Therapy in Cancer: A Meta-Analysis of Randomized Controlled Trials
BACKGROUND: Although combination therapy with immune checkpoint inhibitors (ICIs) provides a promising efficacy in multiple cancers, their use is facing challenges for a high incidence of adverse effects. This meta-analysis was conducted to compare the risks of organ-specific immune-related adverse...
Autores principales: | Da, Lijun, Teng, Yuanjun, Wang, Na, Zaguirre, Karen, Liu, Yating, Qi, Yali, Song, Feixue |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7002539/ https://www.ncbi.nlm.nih.gov/pubmed/32082164 http://dx.doi.org/10.3389/fphar.2019.01671 |
Ejemplares similares
-
Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis
por: Zhang, Yue, et al.
Publicado: (2022) -
Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review
por: Gao, Ling, et al.
Publicado: (2019) -
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
por: Kumar, Vivek, et al.
Publicado: (2017) -
Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System
por: Bai, Xiaoyin, et al.
Publicado: (2021) -
Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
por: Kumar, Vivek, et al.
Publicado: (2017)